NantHealth® to Present New Research Findings at the San Antonio Breast Cancer Symposium
December 03 2018 - 7:00AM
Business Wire
Topics to include DNA and RNA profiling and
next-generation sequencing of tumors
Significant developments in breast cancer research will be
presented by NantHealth (NASDAQ: NH) at the San Antonio Breast
Cancer Symposium this week. NantHealth, a leader in breakthrough
cancer research and solutions to improve patient care and lower
healthcare costs, will discuss the findings of three
investigations, which examine the theme of providing oncologists
with insights that enable cancer treatment tailored to the
individual characteristics of each patient.
The Symposium, which will be held at the Henry B. Gonzalez
Convention Center in San Antonio from Dec. 4-8, is designed to
provide state-of-the-art information on the experimental biology,
etiology, prevention, diagnosis and therapy of breast cancer and
premalignant breast disease, to an international audience of
academic and private physicians and researchers.
“About 1 in 8 U.S. women or about 12.4% will develop invasive
breast cancer over the course of her lifetime. Such staggering
statistics make breast cancer research and progress critical,” said
Sandeep “Bobby” Reddy MD, Chief Medical Officer, NantHealth. “We
are honored to have an integral role at the San Antonio Breast
Cancer Symposium, which provides a dynamic forum for interaction,
communication, and education for a broad spectrum of researchers,
health professionals, and those with a special interest in breast
cancer.”
Title: “Germline potentially pathogenic variants in
breast cancer intrinsic molecular subtypes are not associated with
somatic TMB”Presenting Author: Elias Obeid, MD, MPHSenior
Author: Christopher Szeto, PhDContributors: Sandeep
“Bobby” Reddy MD; Lori J. Goldstein, MD; Mary B. Daly, MD, PhD;
Stephen C. Benz, PhD; and Michael J. Hall, MD,
MSDescription: Comprehensive DNA and RNA profiling of 270
patients revealed intrinsic molecular subtypes of breast cancer
have significantly distinct profiles of pathogenic germline
variants. However, despite some breast cancer subtypes having
higher frequency of germline pathogenic variants within DNA-damage
repair genes, there is little evidence that these patients have
subsequently higher mutational burden within their somatic
genomes.Key Takeaway: Pathogenic germline variants in key
DNA damage repair genes such as BRCA1/2 are likely not adequate
biomarkers for immune checkpoint therapy response, but are
potentially biomarkers of differential tumorigenesis pathways.
Title: “Time-course DNA and RNA profiling of tumors from
intra-patient cross-over trial of sequential use of aromatase
inhibitors”Presenting Author: Charles VaskeSenior
Authors: Vessela Kristensen and Jürgen
GeislerContributors: Rahul Parulkar, Nazli Bahrami, Torill
Sauer, Marie Loeng, Berit Gravdehaug, Belal Aljabri, Vahid
Bemanian, Jonas Lindstrøm and Torben LüdersDescription:
Early analysis from the ongoing NEOLETEXE trial examines a
time-series of biopsies taken while transitioning patients from
steroidal to non-steroidal aromatase inhibitors (AI) and vice
versa. Acquired markers of AI-therapy resistance, and potential
markers of sequential therapy sensitization, were explored. Two
months after initial therapy, mutational burden decreased and
clonality increased, yet by 4mo post-initialization mutations
particularly in PIK3CA had repopulated.Key Takeaway:
Switching AI therapies sequentially in a clinical study is a model
system to study differences in anti-tumor-effects of AIs. This
ongoing trial may lead to a novel strategy to resensitize tumors to
hormonal treatment and to elucidate the differences between
steroidal and non-steroidal AIs.
Title: “Identification of a neoantigen targeted by
tumor-infiltrating lymphocytes in a patient with Her2+ breast
cancer”Presenting Author: Hannah KranichSenior
Authors: Peter A. Fasching and Anita N.
KremerContributors: Andrew Nguyen, Hanna Hübner, Erber
Ramona, Judith Bausenwein, Edith D. van der Meijden, Michael P.
Lux, Sebastian Jud, Claudia Rauh, John Zachary Sanborn, Stephen C.
Benz, Shahrooz Rabizadeh, Matthias W. Beckmann, Andreas Mackensen
and Matthias RübnerDescription: In our study, we identify
tumor infiltrating T-cells (TILS) that recognize tumor specific
mutations (Neoepitopes) found by next-generation sequencing of
breast cancer tumors. These identified TILS are further
immortalized and characterized to bind the patient’s specific HLA
alleles.Key Takeaway: Identification of TILS recognizing
patient specific neoepitopes allow development of personalized
medicine in a pre-clinical setting.
Since 1977, the San Antonio Breast Cancer Symposium mission has
been to provide state-of-the-art information on breast cancer
research. From a one-day regional conference, the Symposium has
grown to a five-day program attended by a broad international
audience of academic and private researchers and physicians from
over 90 countries. For more information visit:
https://www.sabcs.org/2018-SABCS-sup-sup.
About NantHealth
NantHealth, Inc., a member of the NantWorks ecosystem of
companies, uses personalized data to improve patient care and lower
healthcare costs. NantHealth leads the way in providing oncologists
with insights that enable cancer treatment tailored to the
individual characteristics of each patient. NantHealth solutions
reduce the cost of care by connecting patient data and streamlining
the accurate collection and sharing of that data--starting from a
patient’s bedside, extending to payers and providers. NantHealth
improves clinical decision support, eliminates unwarranted care and
seeks to enhance. For more information please visit
www.nanthealth.com.
About NantOmics
NantOmics, a member of the NantWorks ecosystem of companies,
delivers molecular analysis capabilities with the intent of
providing actionable intelligence and molecularly driven decision
support for cancer patients and their providers at the point of
care. NantOmics is the first molecular analysis company to pioneer
an integrated approach to unearthing the genomic variants and
transcriptomic changes that initiate and drive cancer, by analyzing
both normal and tumor cells from the same patient and connecting
drugs to DNA to RNA changes in the tumor. NantOmics has a highly
scalable cloud-based infrastructure capable of storing and
processing thousands of genomes a day. For more information please
visit www.nantomics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181203005184/en/
Media:Jen HodsonNANTjhodson@nantworks.com
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Mar 2024 to Apr 2024
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Apr 2023 to Apr 2024